Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVID-19 vaccine induced immune response in patients with primary antibody deficiency
2021-004891-33Phase 4Completed
- Sponsor
- Turku University Hospital
- Start
- Mar 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of tozinameran, ChAdOx1 nCoV-19 and elasomeran in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Turku University Hospital. Primary endpoint: Immune response to COVID-19 vaccines (primary). Started Mar 2022; status: completed.
02
Drugs
tozinameranChAdOx1 nCoV-19elasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-004891-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004891-33.